Why is Marksans Pharma falling/rising?

As of 05-Jun, Marksans Pharma Ltd is experiencing a slight increase in its stock price, currently at 258.20, reflecting a change of 0.75 or 0.29% upward. Despite this positive movement today, the stock has underperformed its sector by 0.77%. Over the past week, it has seen a minor decline of 0.31%, although it has performed well over the past month with a return of 16.12%. The stock has shown strong performance over the past year, generating a return of 74.93%, significantly outperforming the BSE 500 index. However, there are concerns regarding falling investor participation, as evidenced by a 45.74% drop in delivery volume compared to the 5-day average. The stock's technical trend is currently sideways, indicating a lack of clear price momentum, despite being above shorter-term moving averages.
In the broader market context, the stock's recent performance contrasts with the benchmark Sensex, which has only increased by 0.80% over the past month. While Marksans Pharma has demonstrated high management efficiency with a return on equity (ROE) of 17.66% and low debt levels, its long-term growth prospects appear limited, with operating profit growth averaging only 2.87% over the last five years. Additionally, the stock is considered expensive with a price-to-book value of 4.7, which is above its peers' average historical valuations. Despite the strong returns over the past year, the company's flat results and low inventory turnover ratio raise concerns about its future profitability, contributing to a mixed outlook for investors.